Since their introduction 20 years ago, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolu­tionised the treatment of diabetes and obesity. Known for their immunomodulatory and ...

In a real-world study, patients with psoriatic disease treated with an IL-17 targeted biologic and a GLP-1 agonist ...

The researchers found that GLP-1 RA use was associated with significantly lower odds of vertebral compression fractures compared with nonuse. (HealthDay News) — Glucagon-like peptide 1 receptor ...

GLP-1RAs improved RA disease activity, pain scores, weight, cholesterol, and HbA1c levels in patients with a BMI ≥27. Nearly one-third of patients discontinued GLP-1RA therapy due to gastrointestinal ...

The use of GLP-1 receptor agonists (GLP-1 RAs) was associated with a lower risk for serious infections — particularly respiratory, skin and soft tissue, musculoskeletal, and vascular infections as ...

Treatment with GLP-1RAs led to a reduction in both body weight (pooled mean difference, -9.7kg) and WOMAC pain score (pooled mean difference, -0.49 points). Treatment with glucagon-like peptide-1 ...

GLP-1 receptor agonists are linked to a 55% reduction in mortality risk in women with ovarian cancer, based on a retrospective cohort study. The study utilized data from the TriNetX Research Network, ...

Use of liraglutide or semaglutide therapy does not increase risk for thyroid cancer among patients with type 2 diabetes or obesity.

Experts say that improving heart and metabolic health may be key to helping people with severe mental illness live longer, ...

Anti-obesity drugs such as semaglutide (Ozempic, Wegovy) are also promising for the treatment of alcohol use disorder and alcohol-associated liver disease, as growing evidence suggests they reduce the ...

Over the past decade, the global pharmaceutical industry has witnessed a transformation in the treatment landscape for metabolic disorders, particularly type 2 diabetes and obesity. At the heart of ...